Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas
Levine B, Svoboda J, Nasta S, Porter D, Chong E, Lacey S, Mahnke Y, Melenhorst J, Chew A, Shah G, Hasskar J, Wasik M, Landsburg D, Mato A, Garfall A, Frey N, Shaw P, Marcucci K, Shea J, McConville H, Manvar N, O'Rourke M, Lamontagne A, Bersenev A, Zheng Z, Schuster S, June C. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas. Cytotherapy 2015, 17: s13. DOI: 10.1016/j.jcyt.2015.03.327.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply